JP2001521540A - 虹彩メラノサイトにおけるメラニン生成を阻害するα−メチル−Ｐ−チロシンの使用 - Google Patents
虹彩メラノサイトにおけるメラニン生成を阻害するα−メチル−Ｐ−チロシンの使用Info
- Publication number
- JP2001521540A JP2001521540A JP54502598A JP54502598A JP2001521540A JP 2001521540 A JP2001521540 A JP 2001521540A JP 54502598 A JP54502598 A JP 54502598A JP 54502598 A JP54502598 A JP 54502598A JP 2001521540 A JP2001521540 A JP 2001521540A
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- methyl
- latanoprost
- iris
- melanin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 title claims description 24
- 230000008099 melanin synthesis Effects 0.000 title claims description 12
- 210000002752 melanocyte Anatomy 0.000 title claims description 10
- 230000002503 metabolic effect Effects 0.000 claims abstract description 4
- 238000011458 pharmacological treatment Methods 0.000 claims abstract description 4
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 39
- 229960001160 latanoprost Drugs 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 101710147108 Tyrosinase inhibitor Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000003061 melanogenesis Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000030 antiglaucoma agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 claims 3
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims 1
- 229960004317 unoprostone Drugs 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 24
- 108060008724 Tyrosinase Proteins 0.000 abstract description 18
- 102000003425 Tyrosinase Human genes 0.000 abstract description 17
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 230000019612 pigmentation Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 210000000554 iris Anatomy 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 230000036564 melanin content Effects 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 3
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 210000001943 adrenal medulla Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- GPLIMIJPIZGPIF-UHFFFAOYSA-N 2-hydroxy-1,4-benzoquinone Chemical compound OC1=CC(=O)C=CC1=O GPLIMIJPIZGPIF-UHFFFAOYSA-N 0.000 description 1
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000692783 Chylismia claviformis Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010072289 Eye colour change Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108010037782 cytomedins Proteins 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 208000014432 malignant adrenal gland pheochromocytoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000024181 negative regulation of developmental pigmentation Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- -1 αIsopropyl Ester Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI000939A IT1291633B1 (it) | 1997-04-22 | 1997-04-22 | Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride |
| IT97A000939 | 1997-04-22 | ||
| PCT/EP1998/002365 WO1998047515A1 (en) | 1997-04-22 | 1998-04-21 | THE USE OF α-METHYL-P-TYROSINE TO INHIBIT MELANIN PRODUCTION IN IRIS MELANOCYTES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001521540A true JP2001521540A (ja) | 2001-11-06 |
Family
ID=11376994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54502598A Withdrawn JP2001521540A (ja) | 1997-04-22 | 1998-04-21 | 虹彩メラノサイトにおけるメラニン生成を阻害するα−メチル−Ｐ−チロシンの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6359001B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP0977575B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2001521540A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20010020202A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1255064A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE227577T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU732046B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2287887A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69809408T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0977575T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2187028T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0002100A3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL132503A (cg-RX-API-DMAC7.html) |
| IT (1) | IT1291633B1 (cg-RX-API-DMAC7.html) |
| NO (1) | NO995122L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ500435A (cg-RX-API-DMAC7.html) |
| PL (1) | PL189304B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT977575E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2218159C2 (cg-RX-API-DMAC7.html) |
| SI (1) | SI0977575T1 (cg-RX-API-DMAC7.html) |
| SK (1) | SK284255B6 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998047515A1 (cg-RX-API-DMAC7.html) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015509101A (ja) * | 2012-01-17 | 2015-03-26 | タイム，インコーポレーテッド | 薬学的組成物及び方法 |
| US10010590B2 (en) | 2012-01-17 | 2018-07-03 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US10646552B2 (en) | 2012-01-17 | 2020-05-12 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US11052068B2 (en) | 2012-01-17 | 2021-07-06 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US11534420B2 (en) | 2019-05-14 | 2022-12-27 | Tyme, Inc. | Compositions and methods for treating cancer |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1350521A (zh) | 1999-03-05 | 2002-05-22 | 宝洁公司 | C16不饱和的fp选择性前列腺素类似物 |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US9744237B2 (en) * | 2009-01-29 | 2017-08-29 | Kambiz Thomas Moazed | Method and system for effecting changes in pigmented tissue |
| WO2010087983A1 (en) * | 2009-01-29 | 2010-08-05 | Kambiz Thomas Moazed | Method and system for effecting changes in pigmented tissue |
| US20120076848A1 (en) * | 2009-07-22 | 2012-03-29 | Kambiz Thomas Moazed | Method and system for effecting changes in pigmented tissue |
| US8481498B1 (en) | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
| US9763903B2 (en) | 2013-10-22 | 2017-09-19 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| US9585841B2 (en) | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
| US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| US9326962B2 (en) | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| ES2738248B2 (es) * | 2018-06-21 | 2023-03-10 | Consejo Superior Investigacion | Uso de inhibidores de la tirosina hidroxilasa para el tratamiento del aneurisma de aorta |
| JP2021530568A (ja) | 2018-07-19 | 2021-11-11 | ヤモ・ファーマシューティカルズ・エルエルシー | 自閉症を処置するための組成物および方法 |
| CN116035151A (zh) * | 2023-01-18 | 2023-05-02 | 云南贝泰妮生物科技集团股份有限公司 | 一种刺梨闪释粉及其制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04117313A (ja) * | 1990-09-06 | 1992-04-17 | Kanebo Ltd | 美白化粧料 |
-
1997
- 1997-04-22 IT IT97MI000939A patent/IT1291633B1/it active IP Right Grant
-
1998
- 1998-04-21 HU HU0002100A patent/HUP0002100A3/hu unknown
- 1998-04-21 JP JP54502598A patent/JP2001521540A/ja not_active Withdrawn
- 1998-04-21 ES ES98924164T patent/ES2187028T3/es not_active Expired - Lifetime
- 1998-04-21 US US09/403,524 patent/US6359001B1/en not_active Expired - Fee Related
- 1998-04-21 DE DE69809408T patent/DE69809408T2/de not_active Expired - Fee Related
- 1998-04-21 EP EP98924164A patent/EP0977575B1/en not_active Expired - Lifetime
- 1998-04-21 PL PL98336386A patent/PL189304B1/pl not_active IP Right Cessation
- 1998-04-21 CA CA002287887A patent/CA2287887A1/en not_active Abandoned
- 1998-04-21 PT PT98924164T patent/PT977575E/pt unknown
- 1998-04-21 WO PCT/EP1998/002365 patent/WO1998047515A1/en not_active Ceased
- 1998-04-21 AT AT98924164T patent/ATE227577T1/de not_active IP Right Cessation
- 1998-04-21 AU AU76462/98A patent/AU732046B2/en not_active Ceased
- 1998-04-21 IL IL13250398A patent/IL132503A/en not_active IP Right Cessation
- 1998-04-21 KR KR1019997009782A patent/KR20010020202A/ko not_active Ceased
- 1998-04-21 DK DK98924164T patent/DK0977575T3/da active
- 1998-04-21 RU RU99124771/14A patent/RU2218159C2/ru not_active IP Right Cessation
- 1998-04-21 NZ NZ500435A patent/NZ500435A/en unknown
- 1998-04-21 SI SI9830312T patent/SI0977575T1/xx unknown
- 1998-04-21 SK SK1424-99A patent/SK284255B6/sk unknown
- 1998-04-21 CN CN98804999A patent/CN1255064A/zh active Pending
-
1999
- 1999-10-21 NO NO995122A patent/NO995122L/no not_active Application Discontinuation
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015509101A (ja) * | 2012-01-17 | 2015-03-26 | タイム，インコーポレーテッド | 薬学的組成物及び方法 |
| JP2018065848A (ja) * | 2012-01-17 | 2018-04-26 | タイム，インコーポレーテッド | 薬学的組成物及び方法 |
| US10010590B2 (en) | 2012-01-17 | 2018-07-03 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US10307465B2 (en) | 2012-01-17 | 2019-06-04 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US10646552B2 (en) | 2012-01-17 | 2020-05-12 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US11052068B2 (en) | 2012-01-17 | 2021-07-06 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US11103559B2 (en) | 2012-01-17 | 2021-08-31 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US11534420B2 (en) | 2019-05-14 | 2022-12-27 | Tyme, Inc. | Compositions and methods for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69809408D1 (de) | 2002-12-19 |
| DE69809408T2 (de) | 2003-07-10 |
| NO995122D0 (no) | 1999-10-21 |
| PT977575E (pt) | 2003-03-31 |
| AU7646298A (en) | 1998-11-13 |
| EP0977575A1 (en) | 2000-02-09 |
| HUP0002100A2 (hu) | 2000-11-28 |
| NO995122L (no) | 1999-12-21 |
| ES2187028T3 (es) | 2003-05-16 |
| AU732046B2 (en) | 2001-04-12 |
| EP0977575B1 (en) | 2002-11-13 |
| PL336386A1 (en) | 2000-06-19 |
| DK0977575T3 (da) | 2003-03-10 |
| IL132503A0 (en) | 2001-03-19 |
| CA2287887A1 (en) | 1998-10-29 |
| KR20010020202A (ko) | 2001-03-15 |
| ATE227577T1 (de) | 2002-11-15 |
| HUP0002100A3 (en) | 2003-05-28 |
| SK284255B6 (sk) | 2004-12-01 |
| ITMI970939A0 (cg-RX-API-DMAC7.html) | 1997-04-22 |
| US6359001B1 (en) | 2002-03-19 |
| SK142499A3 (en) | 2000-09-12 |
| ITMI970939A1 (it) | 1998-10-22 |
| SI0977575T1 (en) | 2003-04-30 |
| IL132503A (en) | 2004-06-20 |
| NZ500435A (en) | 2001-09-28 |
| WO1998047515A1 (en) | 1998-10-29 |
| PL189304B1 (pl) | 2005-07-29 |
| IT1291633B1 (it) | 1999-01-11 |
| RU2218159C2 (ru) | 2003-12-10 |
| CN1255064A (zh) | 2000-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001521540A (ja) | 虹彩メラノサイトにおけるメラニン生成を阻害するα−メチル−Ｐ−チロシンの使用 | |
| CA1293504C (en) | Therapeutic use of tin mesoporphyrin | |
| KR20030004349A (ko) | 탈색제로서 멜라닌 색소의 합성에 포함되는 효소들의발현을 조절하는 신종의 올리고뉴클레오티드들 및올리고뉴클레오티드들의 사용방법 | |
| EP0742012A3 (en) | Pharmaceutical composition containing substance inhibiting HSP47 production | |
| JPH09504543A (ja) | 白内障の予防法及び予防手段 | |
| JP2008260782A (ja) | 神経細胞機能の維持、その消失の防止又は回復のためのデプレニル化合部を利用した器具 | |
| Korc et al. | Cytosolic calcium regulates epidermal growth factor endocytosis in rat pancreas and cultured fibroblasts. | |
| US6933282B2 (en) | Regulation of tyrosine hydroxylase by GPE | |
| JP2002528491A (ja) | プロスタグランジン治療の間の虹彩の色素沈着の増加を予防する方法 | |
| SI9720060A (sl) | Uporaba 2-fenil-1,2-benzizoselenazol-3(2H)-ona za pripravo farmacevtskega pripravka za zdravljenje Alzheimerjeve bolezni | |
| EP0838220A1 (en) | Drug for ameliorating brain diseases | |
| US6872751B2 (en) | Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof | |
| Weiner et al. | The regulation of tyrosine hydroxylase activity in adrenergic nervous tissue | |
| HK1027978A (en) | THE USE OF α-METHYL-P-TYROSINE TO INHIBIT MELANDIN PRODUCTION IN IRIS MELANOCYTES | |
| Smith et al. | The antagonism by anti-inflammatory analgesics of prostaglandin F2α-induced contractions of human and rabbit myometrium in vitro | |
| US6066665A (en) | Combination of cis-4-hydroxy-L-proline and N-methyl-cis-4-hydroxy-L-proline for use as a therapeutic agent, in particular in cancer treatment | |
| Nelson et al. | Developmental time courses in the brain and kidney of two enzymes that oxidize γ-hydroxybutyrate | |
| CZ372099A3 (cs) | Použití alfa-methyl-p-tyrosinu k inhibici produkce melaninu v pigmentových buňkách duhovky | |
| US6451818B1 (en) | Therapeutic use of 1,6-dimethyl-8β-hydroxymethyl-10α-methoxyergoline | |
| WO2005016895A1 (en) | Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thinone, its preparation and a depigmentation compositon containing the same as an effective component | |
| Van den Bogert et al. | Inhibition of mitochondrial protein synthesis influences the glucocorticoid sensitivity of lymphoid cells | |
| CA1156148A (en) | Process for reducing depression | |
| FR2925336A1 (fr) | Utilisation de derives dithiolethiones dans les desordres de la pigmentation | |
| Koelle et al. | Histochemical and pharmacological evidence of the function of butyrylcholinesterase | |
| Okamura et al. | Local generation and action of angiotensin II in dog iris sphincter muscle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050215 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20061117 |